Angiogenesis is a double-edged sword; it is a mechanism that defines the boundary
between health and disease. In spite of its central role in physiological homeostasis, it …

Acquired resistance to cell death is a hallmark of cancer. The BCL-2 protein family members
play important roles in controlling apoptotic cell death. Abnormal over-expression of pro …

The B cell leukemia/lymphoma 2 (BCL-2) inhibitor venetoclax is effective in chronic
lymphocytic leukemia (CLL); however, resistance may develop over time. Other lymphoid …

Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …

The MYC transcription factor, encoded by the c‐MYC proto‐oncogene, is activated by
growth‐promoting signals, and is a key regulator of biosynthetic and metabolic pathways …

Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …

As a broad-spectrum oral small molecule inhibitor targeting multikinase, sorafenib is
currently approved for the clinical treatment of several types of cancer as a single agent. A …

Cancer is one of the most common causes of death. So, its lethal effect increases with time.
Near about hundreds of cancers are known in humans. Cancer treatment is done to cure or …

Background Toripalimab is a PD-1 inhibitor that is approved for the treatment of advanced
oesophageal squamous cell carcinoma, but its efficacy in locally advanced disease is …

Discovery of small molecule inhibitors targeting Mcl-1 (Myeloid cell leukemia 1) confronts
many challenges. Based on the fact that Mcl-1 is mainly localized in mitochondria, we …